A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of AEM-28 in Healthy Subjects and Patients With Refractory Hypercholesterolemia

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of AEM-28 in Healthy Subjects and Patients With Refractory Hypercholesterolemia

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs AEM 28 (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions; First in man
  • Sponsors Capstone Therapeutics; LipimetiX
  • Most Recent Events

    • 30 Mar 2015 Status changed from recruiting to completed, according to to ClinicalTrials.gov record.
    • 02 Sep 2014 Top-line data are expected in late fourth quarter 2014 or early first quarter 2015, according to a Capstone Therapeutics media release.
    • 30 May 2014 New source identified and integrated (ClinicalTrials.gov: NCT02100839).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top